Debbie Quinn
- Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES)By Marius Hoeper, Robyn J. Barst, Nazzareno Galié, Paul Hassoun, Nick Morrell, Andrew Peacock, Gérald Simonneau, Victor Tapson, Fernando Torres, Keith Lu, Debbie Quinn and Ardeschir GhofraniMarius Hoeper1Respiratory Medicine, Medizinische Hochschule, Hannover, GermanyRobyn J. Barst2Respiratory Medicine, Columbia University, New York, NY, United StatesNazzareno Galié3Respiratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyPaul Hassoun4Respiratory Medicine, Johns Hopkins University, Baltimore, MD, United StatesNick Morrell5Respiratory Medicine, Addenbrookes and Papworth Hospitals, Cambridge, United KingdomAndrew Peacock6Respiratory Medicine, Golden Jubilee National Hospital, Glasgow, United KingdomGérald Simonneau7Respiratory Medicine, Université Paris-Sud XI, Orsay, FranceVictor Tapson8Respiratory Medicine, Duke University Medical Center, Durham, NC, United StatesFernando Torres9Respiratory Medicine, UT Southwestern Medical Center, Dallas, TX, United StatesKeith Lu10Respiratory Medicine, Novartis Pharmaceuticals, East Hanover, NJ, United StatesDebbie Quinn11Respiratory Medicine, Novartis Pharmaceuticals, Cambridge, MA, United StatesArdeschir Ghofrani12Respiratory Medicine, University Hospital Giessen and Marburg GmbH, Giessen, Germany
- Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertensionBy Thomas Bouillon, Didier Renard, Ping Zhou, Gerard Flesch and Debbie QuinnThomas Bouillon1Modeling and Simulation, Novartis Pharma AG, Basel, SwitzerlandDidier Renard1Modeling and Simulation, Novartis Pharma AG, Basel, SwitzerlandPing Zhou2Drug Metabolism and Pharmacokinetics, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomGerard Flesch1Modeling and Simulation, Novartis Pharma AG, Basel, SwitzerlandDebbie Quinn3Critical Care, Novartis Pharmaceuticals, East Hanover, NJ, United States
- Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertensionBy Didier Renard, Thomas Bouillon, Gerard Flesch, Ping Zhou and Debbie QuinnDidier Renard1Modeling and Simulation, Novartis Pharma AG, Basel, SwitzerlandThomas Bouillon1Modeling and Simulation, Novartis Pharma AG, Basel, SwitzerlandGerard Flesch1Modeling and Simulation, Novartis Pharma AG, Basel, SwitzerlandPing Zhou2Novartis, Drug Metabolism and Pharmacokinetics, Horsham, West Sussex, United KingdomDebbie Quinn3Critical Care, Novartis Pharmaceuticals, East Hanover, NJ, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.